Diclofenac
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Diclofenac: COX inhibitor (NSAID) → hypotrichosis simplex of the scalp
One-Sentence Summary
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclo-oxygenase (COX) enzymes. The TxGNN model predicts it may be effective for hypotrichosis simplex of the scalp, but no clinical trials and no publications currently support this prediction, so it rests on the model prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 0.9969 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for diclofenac is not available in the data compiled for this report. Based on known pharmacology, diclofenac is a COX-1/COX-2 inhibitor that reduces prostaglandin production, which lowers inflammation and pain.
Hypotrichosis simplex of the scalp is a genetic hair-follicle disorder (for example, linked to CDSN or APCDD1 variants). It is not primarily an inflammatory or prostaglandin-driven condition, so there is no clear mechanistic link to COX inhibition. The high TxGNN score is a model-based prediction only. It is not backed by any trial or publication, and it should be treated as a hypothesis with weak biological support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Diclofenac is marketed in India. The data compiled for this report show that all recorded licences are valid single-ingredient products, in oral tablet, sustained-release tablet and injectable forms. This list may be partial, and the licence records carry no approved-indication text.
Safety Considerations
- Drug Interactions: 641 interacting drugs are recorded. Examples at moderate level include acetylsalicylic acid, corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), metformin and sulfonylureas (glimepiride, glipizide, chlorpropamide), aprepitant, mesalazine and balsalazide. Famotidine, ranitidine and cimetidine are minor.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature and no plausible mechanism, since diclofenac’s COX inhibition does not address a genetic hair-follicle disorder. Evidence is at the model-prediction level only (L5).
To proceed, the following is needed:
- Preclinical or mechanistic evidence linking prostaglandin/COX pathways to hair-follicle function in this condition
- Detailed mechanism-of-action data for diclofenac
- Package insert warnings and contraindications for a safety review
- Any clinical or published study that directly addresses this disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.